DYN Q2 2023 Earnings — Dyne Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

DYNDyne Therapeutics, Inc.

$3B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$67M

Net Income

-$65M

EPS (Diluted)

$-1.08

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$56M

Free Cash Flow

-$56M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$251M

Total Liabilities

$45M

Stockholders' Equity

$207M

Cash & Equivalents

$168M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$67M	-$53M	-26.5%
Net Income	-$65M	-$52M	-24.1%